department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Denali Therapeutics Inc. ($DNLI) · pharmadog

PUBLIC COMPANY

$DNLIDenali Therapeutics Inc.

South San Francisco, CA, USupdated 1h ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

3

marketed

1

phase 3

0

catalysts ytd

2

approvals ytd

1

recalls ytd

0

Pipeline(3)

pipeline depth3 products

1Phase 21Marketed1Unknown

tividenofusp alfa

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome )

Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome )

drug

AVLAYAH

1 INDICATIONS AND USAGE AVLAYAH is indicated for the trea…

Upcoming

no upcoming catalysts on record

Recent(90d)

earnings (1)

Denali Therapeutics Inc. earnings

Denali Therapeutics Inc.

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Denali Therapeutics Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$DNLI

SEC CIK

0001714899

country

US

source

sec_tickers

mentioned in

0news items

entity-linker matched

Active trials

phase3An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007enrolling by invitationn=99
phase1A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Diseaserecruitingn=68
phase2Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)recruitingn=50
phase1A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL952 in Adult Participants With Late-Onset Pompe Diseasenot yet recruitingn=32
phase2A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)active not recruitingn=85
phase2Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)active not recruitingn=20
phase2A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndromeactive not recruitingn=47
phase3A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)recruitingn=63

more trials →

Data sources

SEC EDGAR · openFDA

last refreshed 7m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$DNLI25.98+0.58%

$DNLI25.98+0.58%

🐶 often sniffed alongside

top 4

tagApproval2 co-mentions · 1 sources
drugAVLAYAH2 co-mentions · 1 sources
drugtividenofusp alfa2 co-mentions · 1 sources
drugicosapent ethyl1 co-mentions · 1 sources